Sign in Subscribe

Critical Path Institute

C-Path Reaffirms Commitment to Advancing Regulatory Science for Disease-Modifying Therapies in Type 1 Diabetes

C-Path Reaffirms Commitment to Advancing Regulatory Science for Disease-Modifying Therapies in Type 1 Diabetes

Regulatory milestone underscores opportunity for shared regulatory-science and evidence frameworks to support the next generation of therapies. TUCSON, Ariz., June 15, 2026 /PRNewswire/ -- Critical Path Institute® (C-Path), through its Type 1 Diabetes Consortium, today reaffirmed its commitment to strengthening the regulatory-science and evidence infrastructure needed to enable

Critical Path Institute to Convene Drug Development Leaders at 2026 Global Impact Conference

Critical Path Institute to Convene Drug Development Leaders at 2026 Global Impact Conference

Annual conference returns to Washington, D.C., Sept. 15-16; addresses challenges in establishing a new paradigm for how evidence of efficacy and safety is generated. TUCSON, Ariz., June 9, 2026 /PRNewswire/ -- Critical Path Institute® (C-Path) will host its 2026 Global Impact Conference (CGIC) this September at the Washington